Padagis announced two recent ANDA submissions, including an ANDA for a generic version of Hikma's Kloxxado naloxone nasal spray for the reversal of opioid overdose. Kloxxado, which delivers an 8 mg dose of naloxone compared to a 4 mg dose for Narcan nasal spray, was approved by the FDA in April 2021. Padagis launched a generic version of Narcan in the US in June … [Read more...] about Padagis announces submission of ANDA for generic of Kloxxado naloxone nasal spray
News
Resyca announces new Chief Technical Officer, licensing deal with Thaerapy
Soft mist inhaler developer Resyca, a joint venture of Medspray Pharma and Recipharm, has announced the promotion of current Head of Development and Project Management Nicolas Buchmann to Chief Technical Officer. Buchman will take over from Wilbur de Kruijf, who is leaving to serve as CEO of a start-up inhaled drug developer called Thaerapy. Resyca also announced that … [Read more...] about Resyca announces new Chief Technical Officer, licensing deal with Thaerapy
Tiziana announces the promotion of Matthew Davis to Chief Operating Officer
Intranasal foralumab developer Tiziana Life Sciences announced the promotion of its Chief Medical Officer Matthew Davis to Chief Operating Officer. Davis, who joined Tiziana in July 2022, will continue to serve as Chief Medical Officer in addition to his role as COO. His previous experience includes roles at Endo, Lupin, and URL Pharma. According to the company, … [Read more...] about Tiziana announces the promotion of Matthew Davis to Chief Operating Officer
NMPA approves China Medical System’s NDA for diazepam nasal spray for the treatment of seizures
China Medical System Holdings announced that the National Medical Products Administration of China has approved the company's NDA for diazepam nasal spray for the treatment of seizure clusters in epilepsy patients age 6 and older when the seizures are different for the patient's usual pattern of seizures. In the US, the diazepam nasal spray, which is marketed as … [Read more...] about NMPA approves China Medical System’s NDA for diazepam nasal spray for the treatment of seizures
Acadia Pharmaceuticals to develop intranasal carbetocin for the treatment of hyperphagia in PWS
Acadia Pharmaceuticals announced that it will develop ACP-101 (formerly LV-101) intranasal carbetocin for the treatment of excessive hunger in Prader-Willi syndrome (PWS). Acadia acquired the rights to the nasal spray when it acquired Levo Therapeutics in June 2022. Levo had licensed the intranasal carbetocin from Ferring Pharmaceuticals in 2017 and initiated Phase 3 … [Read more...] about Acadia Pharmaceuticals to develop intranasal carbetocin for the treatment of hyperphagia in PWS
Moat Biotechnology raises $6.5 million for development of intranasal/inhaled COVID-19 vaccine
Moat Biotechnology (MoatBio), a spin-out from Tetherex Pharmaceuticals, announced that it has closed a funding round of more than $6.5 million following an initial funding led by Cortado Ventures in September 2022. The company says that it intends to use the proceeds for continued development of an inhaled/intranasal COVID-19 vaccine based on the SC-AdVax single-cycle … [Read more...] about Moat Biotechnology raises $6.5 million for development of intranasal/inhaled COVID-19 vaccine
Gilbert Technologies raises €7 million for development of its soft mist inhaler device
Dutch device company Gilbert Technologies has announced the closing of a €7 million funding round led by DeepTechXL. The company said that Brabant Startup Funds also converted its earlier loan to Gilbert Technologies, making Brabant a shareholder, along with current shareholders NanoCorp and Delft Enterprises. According to Gilbert, the proceeds of the funding will … [Read more...] about Gilbert Technologies raises €7 million for development of its soft mist inhaler device
Vistagen announces results from Phase 2a trial of PH80 epoxyestrenolone nasal spray for the treatment of hot flashes
Vistagen announced that a Phase 2a trial of the company's PH80 intranasal epoxyestrenolone in menopausal women experiencing hot flashes demonstrated statistically significant reduction in the frequency and severity of the hot flashes. The company acquired PH80 when it acquired Pherin Pharmaceuticals earlier this year and the Phase 2a trial was conducted by Pherin at … [Read more...] about Vistagen announces results from Phase 2a trial of PH80 epoxyestrenolone nasal spray for the treatment of hot flashes
InhaleRx initiates Phase 1 trial of IRX211 dronabinol MDI
Australian inhaled cannabis developer InhaleRx (formerly Lifespot Health) announced the initiation of a Phase 1 SAD study of the company's IRX211 inhaled dronabinol, a synthetic THC. According to the company, IRX211 was formulated by "a specialized inhalation expert group based in the UK," and the clinical trial batch was manufactured by Ab Initio Pharma. InhaleRx is … [Read more...] about InhaleRx initiates Phase 1 trial of IRX211 dronabinol MDI
Alpha Cognition gets $750,000 grant from US military for development of ALPHA-1062 intranasal galantamine for the treatment of brain injury
Alpha Cognition announced that the Army Medical Research and Material Command has awarded the company a $750,000 grant to support a pre-clinical study of the possible use of ALPHA-1062 Intranasal galantamine for the treatment of blast-induced mild traumatic brain injury (mTBI). According to Alpha Cognition, the study will be conducted in partnership with the Seattle … [Read more...] about Alpha Cognition gets $750,000 grant from US military for development of ALPHA-1062 intranasal galantamine for the treatment of brain injury